

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/535,000	HATANO ET AL.	
	Examiner GIGI HUANG	Art Unit 1617	
All Participants:		Status of Application: <u>pre-appeal conference, after final rejection</u>	
(1) <u>GIGI HUANG</u> .		(3) _____.	
(2) <u>RICHARD BARTH</u> .		(4) _____.	
Date of Interview: <u>1 November 2010</u>		Time: <u>3:55pm</u>	
Type of Interview: <input checked="" type="checkbox"/> Telephonic <input type="checkbox"/> Video Conference <input type="checkbox"/> Personal (Copy given to: <input type="checkbox"/> Applicant <input type="checkbox"/> Applicant's representative)			
Exhibit Shown or Demonstrated: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No If Yes, provide a brief description: _____.			
Part I.			
Rejection(s) discussed:			
Claims discussed: 1, 5-12.			
Prior art documents discussed:			
Part II.			
SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED: <i>See Continuation Sheet</i>			
Part III.			
<input checked="" type="checkbox"/> It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability. <input checked="" type="checkbox"/> It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.			
<i>/GiGi Huang/ Examiner, Art Unit 1617</i>			
(Applicant/Applicant's Representative Signature – if appropriate)			

Continuation of Substance of Interview including description of the general nature of what was discussed: Discussed the allowance of the subject matter of claim 1 due to the evidence of synergism of the Rho kinase inhibitor (R)- (+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide with the β-blocker is timolol in the reduction of the intraocular pressure. Discussed the rejoinder of claim 5 with amendments to be commensurate in scope with allowable claim 1, with cancellation of the remaining claims. Received call from Applicant agreeing to the amendments on November 23, 2010.